XML 57 R34.htm IDEA: XBRL DOCUMENT v3.10.0.1
Selected Quarterly Financial Data (unaudited)
 12 Months Ended
Dec. 31, 2018
Quarterly Financial Information Disclosure [Abstract]  
Selected Quarterly Financial Data (unaudited) Selected quarterly financial data (unaudited)

2018
December 31
 
September 30
 
June 30
 
March 31
Total revenues
$
2,821,124

 
$
2,847,330

 
$
2,886,953

 
$
2,849,444

Operating income
$
387,908

 
$
289,038

 
$
438,192

 
$
410,686

Attributable to DaVita Inc.:
 
 
 
 
 
 
 
Net income from continuing operations(1)
$
160,332

 
$
73,371

 
$
199,603

 
$
191,015

Net (loss) income from discontinued operations(2)
$
(310,104
)
 
$
(210,167
)
 
$
67,673

 
$
(12,329
)
Net (loss) income
$
(149,772
)
 
$
(136,796
)
 
$
267,276

 
$
178,686

Per share attributable to DaVita Inc.:
 
 
 
 
 
 
 
Basic net income from continuing operations
$
0.97

 
$
0.44

 
$
1.16

 
$
1.07

Basic net (loss) income from discontinued operations
$
(1.87
)
 
$
(1.26
)
 
$
0.40

 
$
(0.07
)
Basic net (loss) income
$
(0.90
)
 
$
(0.82
)
 
$
1.56

 
$
1.00

Diluted net income from continuing operations
$
0.96

 
$
0.44

 
$
1.15

 
$
1.05

Diluted net (loss) income from discontinued operations
$
(1.86
)
 
$
(1.26
)
 
$
0.38

 
$
(0.07
)
Diluted net (loss) income
$
(0.90
)
 
$
(0.82
)
 
$
1.53

 
$
0.98

2017
 
 
 
 
 
 
 
Total revenues
$
2,780,913

 
$
2,765,071

 
$
2,699,399

 
$
2,631,251

Operating income
$
150,337

 
$
395,294

 
$
391,196

 
$
875,928

Attributable to DaVita Inc.:
 
 
 
 
 
 
 
Net income from continuing operations(1)
$
156,210

 
$
152,870

 
$
151,292

 
$
440,905

Net income (loss) from discontinued operations(2)
$
147,186

 
$
(367,346
)
 
$
(24,291
)
 
$
6,792

Net income (loss)
$
303,396

 
$
(214,476
)
 
$
127,001

 
$
447,697

Per share attributable to DaVita Inc.:
 
 
 
 
 
 
 
Basic net income from continuing operations
$
0.86

 
$
0.81

 
$
0.79

 
$
2.29

Basic net income (loss) from discontinued operations
$
0.80

 
$
(1.95
)
 
$
(0.13
)
 
$
0.04

Basic net income (loss)
$
1.66

 
$
(1.14
)
 
$
0.66

 
$
2.33

Diluted net income from continuing operations
$
0.85

 
$
0.80

 
$
0.78

 
$
2.26

Diluted net income (loss) from discontinued operations
$
0.79

 
$
(1.92
)
 
$
(0.13
)
 
$
0.03

Diluted net income (loss)
$
1.64

 
$
(1.12
)
 
$
0.65

 
$
2.29



 
 
(1)
Included in the fourth quarter of 2018 is a net gain on changes in ownership interests of $28,152; an equity investment loss of $8,715 due to the sale of the APAC JV's India business; and an equity investment loss of $1,530 due to impairments at the APAC JV. The third quarter of 2018 includes restructuring charges of $11,366 and other asset impairment charges of $6,093 related to the Company's pharmacy business; an equity investment loss of $5,995 due to impairments at the APAC JV; an adjustment to the gain on changes in ownership interests on the sale of the Company's direct primary care business of $1,506; and $23,470 in additional stock-based compensation expense related to modification charges and net acceleration of expense. The second quarter of 2018 includes asset impairment charges of $11,245 related to the pharmacy business; a net gain on changes in ownership interests of $35,205 on the Company's direct primary care business; a loss of $1,248 related to the unwinding of a business internationally; and a goodwill impairment charge of $3,106 at the Company's German other health operations. Included in the fourth quarter of 2017 was an impairment of $280,066 on the Company's investment in the APAC JV. The third quarter of 2017 included an equity investment loss of $6,293 for goodwill impairments at the APAC JV and restructuring charges in the Company's international business of $2,700. The second quarter of 2017 included goodwill impairment charges of $10,498 related to the vascular access reporting unit. The first quarter of 2017 included a net gain on settlement of $529,504; goodwill impairment charges of $24,198 related to the vascular access reporting unit; an asset impairment of $15,168 related to the restructuring of the pharmacy business; and a gain adjustment on the 2016 ownership change of the APAC JV of $6,273.
(2)
Included in discontinued operations in the fourth quarter of 2018 is a $218,639 disposal group valuation adjustment, a $41,537 goodwill impairment charge and $8,318 in related tax benefit. The third quarter of 2018 includes a $216,147 charge on the Company's DMG business which included a $98,201 disposal group valuation adjustment and $117,946 in related tax expense on this held-for-sale business. The second quarter of 2018 includes a gain on the sale of the Company's Tandigm investment of $25,096. The fourth quarter of 2017 includes a net tax benefit of $163,555 due to a remeasurement of deferred taxes resulting from DMG's reclassification to held for sale. The third quarter of 2017 includes goodwill impairment charges of $601,040 related to certain DMG reporting units; a non-cash gain associated with the Company's Magan acquisition of $17,129; restructuring charges of $9,569; and a reduction in estimated accruals for legal matters of $11,100. The second quarter of 2017 includes goodwill impairment charges of $50,619 related to certain DMG reporting units and a reduction in estimated accruals for legal matters of $3,600.